TAG:
biopsies
National Anatomic Pathology Companies Continue to Grow
IT’S BOOM TIME IN ONE SEGMENT of the clinical laboratory world. The national anatomic pathology companies are posting record rates of growth and profits. The sustained and strong financial performance at DIANON Systems, Inc. and IMPATH, Inc. has not gone unnoticed…
AmeriPath Pursues Ambitious Strategy Of Rapid Expansion
CEO SUMMARY: As the pathology profession’s only publicly-traded physician practice management company, AmeriPath is the spear point of far-reaching changes now transforming pathology. With an annual revenue run rate of $270 million and an ample war chest of growth capital, AmeriPath int…
Pathology Profession Facing New Directions
CEO SUMMARY: Big changes ahead during the next decade. Among the predictions: the number of two and three-pathologist group practices will radically diminish; pathology centers of excellence will achieve new market dominance; and…ever more intense competition for anatomic pathology spec…
Individual Pathologist “Branding” Promoted by National Firms
IN THE EFFORT TO GAIN COMPETITIVE market advantage, IMPATH, Inc. of New York City publicized the recent signing of an exclusive partnership agreement involving renowned pathologist Juan Rosai, M.D., also of New York City. Dr. Rosai has a world-wide reputation for his books, book cha…
SBCL Makes System-Wide Commitment To AutoPap
SOMEONE ALWAYS HAS TO BE FIRST to adopt new technology. In the case of automated cytology, it will be SmithKline Beecham Clinical Laboratories (SBCL). SBCL and NeoPath, Inc. announced a four-year national agreement between the two companies on October 9 which will e…
“Disease Management” Firms, Niche Labs Release Financials
Two DISEASE MANAGEMENT FIRMS enjoyed strong revenue growth during the first quarter of 1998. UroCor, Inc. and Impath Inc. posted revenue increases of 31% and 49%, respectively, over first quarter 1997. UroCor is the disease management company which serves urologists…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.